Clinical Trials Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Rectal Cancer Therapy
Reports summarize rectal cancer therapy study results from University of Frankfurt
August 27th, 2007
Researchers detail in "Integration of novel agents into combined-modality treatment for rectal cancer patients," new data in rectal cancer. "With optimized local treatment--achieved through preoperative radiochemotherapy (RCT) and total mesorectal excision (TME) surgery--distant metastases are by far the predominate sites of tumor failure in rectal cancer today. The challenge is to integrate more effective systemic therapy into combined-modality programs. Capecitabine, oxaliplatin, irinotecan as well as targeted therapies improved results for colorectal cancer patients when treated in the metastatic and adjuvant setting," scientists in Germany report. "These agents have...
Source: Clinical Trials Week (2007-08-27)
|
